Jagson Pal Pharmaceuticals Limited.

BSE: 507789 NSE: JAGSNPHARM
Jagson Pal Pharmaceuticals Limited. - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
CIN L74899DL1978PLC009181 Incorporated 17 August 1978 ROC Delhi HQ New Delhi, Delhi, India
Active Listed - NSE: JAGSNPHARM · BSE: 507789 Public Limited Company pharma
Data last updated
Market Cap
₹1,427 Cr
JAGSNPHARM · NSE
Share Price
₹216.33
+0.11% today
Revenue
₹287 Cr
FY 2025-26 · +6.9% YoY
EBITDA
₹56.00 Cr
Margin 19.5%
Net Profit
₹44.65 Cr
FY 2025-26 · +41.3% YoY
P/E (TTM)
30.2x
P/B 5.9x
ROE
16.7%
ROCE 21.8%
Debt / Equity
0.03
Interest cover 2.2x

About Jagson Pal Pharmaceuticals Limited.

Data last updated:

Jagson Pal Pharmaceuticals Limited. is a public limited company based in New Delhi, Delhi, India, a subsidiary of Aresko Progressive Private Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 17 August 1978 and has been in existence for over 48 years.

The company is registered with the Registrar of Companies (ROC), Delhi, under CIN L74899DL1978PLC009181. Its GSTIN is 07AAACJ1408L1ZQ (Delhi). The company holds 22 GST registrations, of which 19 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 507789 and NSE: JAGSNPHARM.

The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹13.43 Cr. It was formerly known as Jagson Pal Pharmaceuticals Private Limited. It is led by directors including Manish Gupta (Managing Director) and Radhika Madhukar Dudhat.

Its last annual general meeting (AGM) was held on 24 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Innov8 3rd Floor Plot No. 211, Okhla Phase – 3 New Delhi, Delhi, India – 110020.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹287.23 Cr, a growth of 6.9% compared to the previous year. For the same year it recorded a net profit of ₹44.65 Cr (net margin 15.5%) and EBITDA of ₹56 Cr (EBITDA margin 19.5%). The net worth stands at ₹276.17 Cr (up 15.1% YoY). Total assets are valued at ₹285.51 Cr (up 13.8% YoY).

The company has about 1,308 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Jagsonpal. As per MCA filings, the company has satisfied charges of ₹80.8 Cr on record. Court records list 49 cases involving the company, including 35 filed by the company and 14 filed against it; 8 cases are pending. The company has 38 deals on record (36 market trades, 2 secondary share transfers); the latest was in July 2026. Its 8 peer companies in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Arene Life Sciences (Unit 3) Private Limited with revenue of ₹287.8 Cr. The company has 14 MSME Form 1 returns on record between 2019 and 2024, listing 107 overdue payments to 39 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website jagsonpal.com.

Company details

CIN L74899DL1978PLC009181
Registration Number 009181
Incorporation Date 17 August 1978
ROC Delhi
Listing Status Listed - Listed on NSE (JAGSNPHARM); Listed on BSE (507789)
Company Status Active
Date of Last AGM 24 September 2025
Date of Balance Sheet 31 March 2026
Parent Company Aresko Progressive Private Limited
Compliance Status Active Compliant

CIN history

Jagson Pal Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U74899DL1978PLC009181. The current CIN is L74899DL1978PLC009181, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74899DL1978PLC009181Current
U74899DL1978PLC009181Previous
Key People
Manish Gupta Managing Director Radhika Madhukar Dudhat Director Harsha Raghavan Director

Contact details

Jagson Pal Pharmaceuticals Limited.'s registered office is in New Delhi, Delhi. Its website is jagsonpal.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    jagsonpal.com
  • Social Media
  • Registered Address
    Innov8 3rd Floor Plot No. 211, Okhla Phase – 3 New Delhi, Delhi, India – 110020
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Jagson Pal Pharmaceuticals Limited., buy the company report.

Comprehensive company report
Jagson Pal Pharmaceuticals Limited. - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Jagson Pal Pharmaceuticals Limited operates one associated brand: Jagsonpal. Each brand links to its own profile.

BrandDescriptionWebsite
Jagsonpal
Traditional company manufacturing bulk drugs and finished formulationsjagsonpal.com

Business activity

The main business activity of Jagson Pal Pharmaceuticals Limited is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Jagson Pal Pharmaceuticals Limited., buy the company report.

Financials of Jagson Pal Pharmaceuticals Limited.

FY 2025-26 filings available

Jagson Pal Pharmaceuticals Limited. reported revenue of ₹287.23 Cr (up 6.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹287 Cr
+6.9% YoY
EBITDA
₹56.00 Cr
+18.1% YoY
Profit After Tax
₹44.65 Cr
+41.3% YoY
Net Worth
₹276 Cr
+15.1% YoY
Total Assets
₹286 Cr
+13.8% YoY
Total Debt
₹8.17 Cr
-11.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue287269209237218188159
Revenue growth+6.9%+28.8%-11.8%+8.8%+15.8%+18.5%-
EBITDA56.0047.4123.0630.6925.0119.098.54
EBITDA margin+19.5%+17.6%+11.1%+13.0%+11.5%+10.2%+5.4%
Profit before tax57.5369.8729.8734.8026.6221.889.43
Net profit44.6531.6022.4628.6018.3417.067.91
Net profit margin+15.6%+11.8%+10.8%+12.1%+8.4%+9.1%+5.0%
EPS (₹)6.438.348.5010.207.206.513.00
Balance sheet
Total assets286251197166134129116
Net worth276240187159133122111
Total debt8.179.248.946.000.006.794.66
Cash & bank10612914811525.2560.2338.07
Net working capital11613717913860.3183.6166.75
Cash flow
Cash from operations46.8155.1135.1746.666.9128.2211.25
Cash from investing(35.65)(45.15)(24.55)(57.67)(25.78)(2.26)(10.76)
Cash from financing(12.15)(11.70)(8.91)(0.46)(17.55)(6.83)(0.94)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue81.3882.2364.2072.9574.4775.6158.5674.03
Revenue growth (YoY)+9.3%+8.8%+9.6%-1.5%-0.3%+23.1%--
Other income2.232.833.172.983.032.832.7725.51
Total expenses64.8464.9953.0458.7658.0361.4050.0658.19
EBITDA16.5417.2411.1614.1916.4414.218.5015.84
EBITDA margin+20.3%+21.0%+17.4%+19.5%+22.1%+18.8%+14.5%+21.4%
Depreciation1.682.142.322.392.392.352.312.41
Interest0.250.250.250.260.270.250.260.26
Profit before tax16.8417.6811.7614.5216.8114.448.7038.68
Tax4.244.492.993.574.243.642.136.68

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 02 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue81.3882.2364.2072.9574.4775.6158.5674.03
Revenue growth (YoY)+9.3%+8.8%+9.6%-1.5%-0.3%+23.1%--
Other income2.232.833.172.983.032.832.7725.51
Total expenses64.8464.9953.0458.7658.0361.4050.0658.19
EBITDA16.5417.2411.1614.1916.4414.218.5015.84
EBITDA margin+20.3%+21.0%+17.4%+19.5%+22.1%+18.8%+14.5%+21.4%
Depreciation1.682.142.322.392.392.352.312.41
Interest0.250.250.250.260.270.250.260.26
Profit before tax16.8417.6811.7614.5216.8114.448.7038.68
Tax4.244.492.993.574.243.642.136.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue287269209237218188159
Revenue growth+6.9%+28.8%-11.8%+8.8%+15.8%+18.5%-
Other income12.0031.559.285.733.434.392.53
Total expenses231221186206193169150
Employee cost70.7470.9362.0965.1857.6853.9850.37
EBITDA56.0047.4123.0630.6925.0119.098.54
EBITDA margin+19.5%+17.6%+11.1%+13.0%+11.5%+10.2%+5.4%
Depreciation9.448.131.661.211.531.091.13
Interest1.030.960.810.410.290.510.51
Profit before tax57.5369.8729.8734.8026.6221.889.43
Tax14.4414.507.418.097.784.821.54
Net profit44.6531.6022.4628.6018.3417.067.91
Net profit margin+15.6%+11.8%+10.8%+12.1%+8.4%+9.1%+5.0%
EPS (₹)6.438.348.5010.207.206.513.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.3913.2813.2213.1013.1013.1013.10
Reserves & surplus26122617414612010997.93
Shareholders' funds (net worth)276240187159133122111
Secured loans0.000.000.000.000.000.00(1.74)
Unsecured loans8.179.248.946.000.006.796.40
Total debt8.179.248.946.000.006.794.66
Total liabilities286251197166134129116
Assets
Gross block10210311.5933.2258.1360.1255.83
Net block85.3194.459.3024.2822.6025.7222.09
Capital work in progress0.000.000.000.000.000.004.25
Investments0.000.000.001.1250.6715.3111.39
Inventories14.6415.2015.0020.6829.7429.7229.33
Sundry debtors17.1913.1810.9520.8715.5812.6621.45
Cash & bank balances10612914811525.2560.2338.07
Loans & advances5.134.0822.908.3916.7114.616.06
Total current assets14316119716587.2811794.91
Total current liabilities26.7224.2917.7526.8226.9733.6128.16
Net working capital11613717913860.3183.6166.75
Total assets286251197166134129116
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.0312.7611.0522.5358.9439.8138.53
Net cash from operating activities46.8155.1135.1746.666.9128.2211.25
Net cash from investing activities(35.65)(45.15)(24.55)(57.67)(25.78)(2.26)(10.76)
Net cash from financing activities(12.15)(11.70)(8.91)(0.46)(17.55)(6.83)(0.94)
Net change in cash(0.99)(1.73)1.71(11.47)(36.42)19.13(0.46)
Closing cash10612914811525.2560.2338.07
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.9%+28.8%-11.8%+8.8%+15.8%+18.5%-
EBITDA growth+18.1%+105.6%-24.9%+22.7%+31.0%+123.5%-
PBT growth-17.7%+133.9%-14.2%+30.7%+21.7%+132.0%+4.8%
Net income growth+41.3%+40.7%-21.5%+55.9%+7.5%+115.7%-
Revenue CAGR (3Y)+6.7%+7.3%+3.6%+14.3%+9.3%+14.1%+3.3%
EBITDA CAGR (3Y)+22.2%+23.8%+6.5%+53.2%+38.9%-+14.0%
Profitability & leverage
Net income margin+15.0%+20.6%+10.8%+11.3%+8.7%+9.1%+5.0%
Return on capital employed+21.8%+22.8%+16.9%+23.5%+21.1%+19.6%+9.5%
Return on net worth+16.7%+14.8%+13.0%+18.3%+15.3%+15.7%+7.9%
Debt / equity0.030.040.040.020.030.050.04
Long-term debt / equity0.030.040.040.020.000.000.00
Interest cover2.212.443.791.391.242.836.88
Efficiency & per share
Fixed asset turnover2.804.689.315.183.943.753.33
Inventory turnover19.2517.8011.709.397.326.375.11
Debtors turnover18.9222.2713.1212.9915.4111.027.52
EPS (₹)6.438.348.5010.207.206.513.00
Dividend per share (₹)4.002.505.005.004.001.000.50
Book value per share (₹)41.0136.0870.8860.6550.6843.5539.39

To see the full year-wise statements and ratios of Jagson Pal Pharmaceuticals Limited., buy the company report.

Board of directors of Jagson Pal Pharmaceuticals Limited.

Jagson Pal Pharmaceuticals Limited has 6 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Radhika Madhukar Dudhat
Also directs: Bajel Projects Limited, Camlin Fine Sciences Limited, Tips Films Limited and 1 more
Director29 Jun 20224 Years 4 MonthsCurrent
Harsha Raghavan
Also directs: Camlin Fine Sciences Limited, Convergent Finance LLP, Sundrop Brands Limited and 5 more
Director29 Jun 20224 Years 4 MonthsCurrent
Debasis Bikash Nandy
Also directs: Traveljunkie Solutions Private Limited, TC Tours Limited, Sotc Travel Limited and 3 more
Director29 Jun 20224 Years 4 MonthsCurrent
Pallavi Dinodia Gupta
Also directs: S R Dinodia & Co LLP, Lumax Industries Limited, Indiamart Intermesh Limited and 2 more
Director29 Jun 20224 Years 4 MonthsCurrent
Manish Gupta
Also directs: Solara Active Pharma Sciences Limited, Synthix Global Pharma Solutions Limited, Intron Life Sciences Private Limited
Managing Director16 Jul 20224 Years 3 MonthsCurrent
Prithipal Singh Kochhar
Also directs: Aresko Global LLP, I.K. Enterprises Private Limited, Suvinys Developers Private Limited and 5 more
Director29 Jun 20224 Years 4 MonthsCurrent
View all directors

Peer comparison

Jagson Pal Pharmaceuticals Limited. is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Arene Life Sciences (Unit 3) Private Limited₹287.8 Cr (FY 2025)53.0%Hyderabad, Telangana, India
Gracure Pharmaceuticals Limited₹287.44 Cr (FY 2025)27.0%New Delhi, Delhi, India
Jagson Pal Pharmaceuticals Limited.this company₹287.23 Cr (FY 2026)₹44.65 Cr15.5%6.9%1,308New Delhi, Delhi, India
Cdymax (India) Pharma Private Limited₹284.85 Cr (FY 2025)12.0%Bangalore, Karnataka, India
Vijayasri Organics Private Limited₹280.5 Cr (FY 2025)16.0%Hyderabad, Telangana, India
Embio Limited₹274.76 Cr (FY 2025)49.0%Mumbai, Maharashtra, India
Multani Pharmaceuticals Limited₹274.25 Cr (FY 2025)2.0%New Delhi, Delhi, India
Sodium Metal Pvt Ltd₹273.32 Cr (FY 2023)-11.0%Vadodara, Gujarat, India
Saraf Chemicals Private Limited₹271.96 Cr (FY 2025)16.0%Mumbai, Maharashtra, India

To see the full peer comparison of Jagson Pal Pharmaceuticals Limited., buy the company report.

Auditor

Jagson Pal Pharmaceuticals Limited. is audited by Walker Chandiok & Co LLP for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Walker Chandiok & Co LLPFY 2024001076N/N500013

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 69.00%, foreign institutional investors hold 2.30%, domestic institutional investors hold 0.60% and retail and other public shareholders hold 28.10%.

Promoters: 69.00%DII (Domestic Institutional): 0.60%FII (Foreign Institutional): 2.30%Retail & Others: 28.10%
Sep 2026
QUARTER
69.00% Promoters
0.60% DII (Domestic Institutional)
2.30% FII (Foreign Institutional)
28.10% Retail & Others
Promoter holding - history
Now 69.00% · Sep 2026High 69.00% · Sep 2026Low 67.40% · Mar 2026
66%67%68%69%70%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 67.50%Mar 2026: 67.40%Jun 2026: 67.90%Sep 2026: 69.00%67.40%69.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters69.00%67.90%67.40%67.50%
Public31.00%32.10%32.60%32.50%

Charges & borrowings

Open charges
None
Satisfied charges
₹80.8 Cr
Breakdown by lending institutions
Punjab & Sind Bank₹60.90 Cr
Others₹19.90 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
26 Oct 201010249872Punjab & Sind Bank₹6.7 CrSatisfied
26 Oct 201010249896Punjab & Sind Bank₹30 LakhSatisfied
26 Oct 201010252531Punjab & Sind Bank₹31.9 CrSatisfied
28 Jun 200610017033Punjab & Sind Bank₹22 CrSatisfied
28 Jun 200610017040Others₹19.9 CrSatisfied

To see the full charge records of Jagson Pal Pharmaceuticals Limited., buy the company report.

Total charge records: 5 View all charges

Deals & funding

Jagson Pal Pharmaceuticals Limited. has 38 deals on record (36 market trades, 2 secondary share transfers); the latest was in July 2026.

Total deals
38
Market trades
36
Secondary share transfers
2

Deals on record (5 of 38)

WhenDealAmountParties
Jul 2026Market trade₹48.77 CrBuyer: NK Securities Research Private Limited , Microcurves Trading Private Limited , Silverleaf Capital Services Private Limited
Seller: NK Securities Research Private Limited , Microcurves Trading Private Limited , Silverleaf Capital Services Private Limited
Jun 2026Market trade₹26.9 CrBuyer: NK Securities Research Private Limited , Qe Securities LLP
Seller: NK Securities Research Private Limited , Qe Securities LLP
Jul 2025Market trade₹24.93 CrBuyer: Graviton Research Capital LLP , Hrti Private Limited
Seller: Graviton Research Capital LLP , Hrti Private Limited
Feb 2022Market trade₹17.68 CrBuyer: Rajasthan Global Securities Private Limited , NK Securities Research Private Limited , XTX Markets LLP
Seller: NK Securities Research Private Limited , Rajasthan Global Securities Private Limited , XTX Markets LLP
Feb 2022Market trade₹10.47 CrBuyer: Graviton Research Capital LLP , XTX Markets LLP , NK Securities Research Private Limited
Seller: Graviton Research Capital LLP , XTX Markets LLP , NK Securities Research Private Limited

To see the full deal history of Jagson Pal Pharmaceuticals Limited., buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Jagson Pal Pharmaceuticals Limited. was last rated by Icra on 30 Sep 2021.

Rating agencyRated onRating
Icra30 Sep 2021

To see the full credit ratings and regulatory alerts of Jagson Pal Pharmaceuticals Limited., buy the company report.

MSME payment delays

Jagson Pal Pharmaceuticals Limited. has 14 MSME Form 1 returns on record between 2019 and 2024, listing 107 overdue payments to 39 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 39)

SupplierAmount dueDue sinceReported on
Kant Drugs Private Limited
Resonance Laboratories Private Limited
an individual supplier
Ekta Corporation
Creative Sense Private Limited

To see the full MSME payment records of Jagson Pal Pharmaceuticals Limited., buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Jagson Pal Pharmaceuticals Limited. has a workforce of 1,308 employees on its EPFO records as of Feb 28, 2025, across 1 active EPFO establishment.

Employee count
1,308
Active EPFO establishments
1
Employee growth
28.99%

GST

Jagson Pal Pharmaceuticals Limited has 22 GST registrations: 19 active and 3 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
22
Active
19
Cancelled / inactive
3
GSTINStateStatusRegistered on
07AAACJ1408L1ZQDelhiActive01 Jul 2017
02AAACJ1408L1Z0Himachal PradeshActive01 Jul 2017
03AAACJ1408L1ZYPunjabActive01 Jul 2017
05AAACJ1408L1ZUUttarakhandActive01 Jul 2017

To see the full GST registrations and return filing status of Jagson Pal Pharmaceuticals Limited., buy the company report.

Recent activity

Jagson Pal Pharmaceuticals Limited. has 38 board changes on record since 1978: 22 appointments and 16 cessations. The latest: Sachin Jain ceased to be CFO on 08 Jul 2025.

Filing
Jagson Pal Pharmaceuticals Limited. has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Delhi I.
AGM
Jagson Pal Pharmaceuticals Limited. last Annual general meeting of members was held on 24 Sep 2025 as per latest MCA records.
Ceased
Sachin Jain ceased to be CFO.
Appointed
Sachin Jain was appointed as CFO.
Ceased
Ashish Lakhotia ceased to be CFO.
Appointed
Ashish Lakhotia was appointed as CFO.
Ceased
Salapaka Venkata Subha Rao ceased to be CFO.
Appointed
Manish Gupta was appointed as Managing Director.
Ceased
Rajpal Singh Kochhar ceased to be Managing Director.
Ceased
Ashok Kumar Pati ceased to be Additional Director.
Ceased
Bharat Sinh ceased to be Director.
Appointed
Debasis Bikash Nandy was appointed as Director.

40 earlier events are in the company report.

News

JAGSNPHARM: Q2 REVENUE 814M RUPEES VS 745M (YOY)
28 Oct 2026 · Exchange Update
JAGSNPHARM: Q2 SL NET PROFIT 126M RUPEES VS 126M (YOY)
28 Oct 2026 · Exchange Update
JAGSNPHARM: Q2 EBITDA 165M RUPEES VS 165M (YOY); Q2 EBITDA MARGIN 20.29% VS 22.15% (YOY)
28 Oct 2026 · Exchange Update
Jagsonpal Pharmaceuticals: Purchases Wellness Segment Of Group Pharmaceuticals For Up To ₹46.7 Crore Through Slump Sale.
23 Sep 2026 · Exchange Update

Frequently asked questions

Jagson Pal Pharmaceuticals Limited is an active public limited company based in New Delhi, Delhi, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 17 August 1978 (48+ years old) and is registered under CIN L74899DL1978PLC009181. Listed on BSE: 507789 and NSE: JAGSNPHARM.

Jagson Pal Pharmaceuticals Limited reported revenue of ₹287.23 Cr for FY 2025-26 (up 6.9% YoY) based on standalone financials.

Jagson Pal Pharmaceuticals Limited has 6 current directors:

The latest financial statements of Jagson Pal Pharmaceuticals Limited on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 24 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Jagson Pal Pharmaceuticals Limited is 07AAACJ1408L1ZQ, registered in Delhi. The company has 22 GST registrations in all, of which 19 are active and 3 are cancelled or inactive. Other active GSTINs include 02AAACJ1408L1Z0 (Himachal Pradesh), 03AAACJ1408L1ZY (Punjab), 05AAACJ1408L1ZU (Uttarakhand).

The CIN (Corporate Identification Number) of Jagson Pal Pharmaceuticals Limited is L74899DL1978PLC009181. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Jagson Pal Pharmaceuticals Limited is a listed company as per MCA records. Its shares are listed on both BSE (code: 507789) and NSE (symbol: JAGSNPHARM).

Jagson Pal Pharmaceuticals Limited has 49 court cases on record: 35 filed by the company and 14 filed against it. 8 are pending. Most are in the district courts.

Jagson Pal Pharmaceuticals Limited was incorporated on 17 August 1978, making it 48+ years old. It is registered with the Registrar of Companies, Delhi.

Jagson Pal Pharmaceuticals Limited has 38 deals on record (36 market trades, 2 secondary share transfers); the latest was in July 2026.

The peers of Jagson Pal Pharmaceuticals Limited by revenue are Arene Life Sciences (Unit 3) Private Limited, Gracure Pharmaceuticals Limited, Cdymax (India) Pharma Private Limited, Vijayasri Organics Private Limited, Embio Limited and 3 more, all in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Sachin Jain ceased to be CFO on 08 Jul 2025. Sachin Jain was appointed as CFO on 05 Feb 2025. Ashish Lakhotia ceased to be CFO on 22 Jan 2025. Jagson Pal Pharmaceuticals Limited has 38 board changes on record in total.